Cambridge, UK, 18 May 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced a target discovery, option and license agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement, facilitated by Johnson & Johnson Innovation, will leverage Mestag’s specialist fibroblast sub-population biology platform and state-of-the-art data analytics to identify novel therapeutic targets.
Under the terms of the agreement, Mestag will interrogate fibroblast…
The latest issue of Sequence looks at key legal and business issues affecting the sector.
Science park investment/ Patents for ground-breaking inventions/ Shaping the EU-UK relationship/ The new life sciences legal framework and much more:
https://update.mills-reeve.com/12/2613/may-2021/life-sciences---sequenc…
Giggabox is set to dramatically scale its Virtual & Hybrid Events offerings to clients as we have secured sizeable investment. This funding has been received from First Enterprise – Enterprise Loans through the Midlands Engine Investment Fund (MEIF). These extra resources will be utilised for the purchase of additional remote digital production equipment and for hiring seven new production and technical employees to help meet the growing demand for live online conferences, product launches, and digital events.
A Few Quotes from Key Stakeholders
Paul Musselle, CEO of Giggabox, commented “…
001 Limited, an independent commercial energy and utility specialists, have recently joined One Nucleus and are excited to start connecting with fellow members from the Life Science industry.
Since 2001, 001 Limited has been using its expertise and experience of the energy market to help businesses across all industries to source sustainable solutions, secure competitive utility contracts and recover savings through conducting historic audits.
At this difficult economic time for businesses across the UK and the growing global climate crisis; 001 Limited is ready to help businesses with their…
COVID-19 swept the globe during 2020 leading to significant morbidity and mortality, impacting all aspects of life, including health and social care provision. This report, published today, demonstrates how people living with rare conditions were disproportionately affected.
In early 2020 a cross-sector group of concerned advocates came together to take Action for Rare Disease Empowerment (ARDEnt). They aimed to shed light on the unseen impact of the pandemic on people living with rare conditions to protect the precious existing services and build on any opportunities uncovered.
Information…
AMSBIO has announced a new range of AAV reference materials of full capsids and empty capsids of 6 different serotypes.Critical to enable meaningful comparisons between research studies and clinical trials, these well-characterized reference standards are extensively quality analyzed with molecular based assays and transmission electron microscope.Gene therapy researchers have long expressed the importance of well characterized AAV reference materials. Recombinant adeno-associated virus (rAAV) is a widely used gene delivery tool for research and clinical applications. Following…
"The acquisition of FGL enables NEB to combine our expertise in enzyme manufacturing and assay development with their expertise in lyophilization, providing a complete solution for our customers," states Jim Ellard, CEO of New England Biolabs. "It also further solidifies our ability to service customers in the molecular diagnostics space."
Martin Lee, Co-founder CEO of Fluorogenics, Ltd., states, "We are delighted to become part of an organization with which we share ideals, innovation and technical excellence, a passion to make a difference through the delivery of scientific solutions that…
Building a robust global patent portfolio for its ArestatTM platform
Cambridge, UK., 13 May 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the grant by the United States Patent and Trademark Office of U.S. Utility Patent No. 10,925,965 B2, a patent that contributes to the Company’s global patent portfolio underpinning its ArestatTM technology platform. This US patent claims proprietary formulation technology aimed at enabling stabilised multi-dose protein products that are desirable in the…
Cambridge, UK: 12 May 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes facilitating connections between companies and expert services that enable members to operate safely, efficiently and with savings against key purchased items. The Group Purchasing Scheme saves members over £3M per annum via negotiated Preferred Supplier Agreements. Circular1 Health, a leading provider of Covid-19 testing to…
Cambridge, 12th May 2021: The Babraham Research Campus’ vision is to be one of the best places in the world for discovery bioscience research and innovation; a leading sustainable ecosystem to start, nurture, scale and grow bioscience business.
Already one of the UK’s leading locations to support world leading discovery research and early-stage bioscience enterprise, the Campus partners (The Babraham Institute, the Biotechnology and Biological Sciences Research Council, and Babraham Bioscience Technologies Ltd) have recently undertaken a strategic review of the Campus and the opportunity for…